News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
XOMA (US) LLC Says Antibody Lowers Blood Sugar in Diabetics
September 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, Sept 8 (Reuters) - U.S. biotechnology company Xoma Ltd said on Monday that a single dose of its experimental antibody has been shown in early-stage trials to improve blood sugar control in patients with type 2 diabetes.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
·
3 min read
·
Jennifer Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
·
1 min read
·
BioSpace Insights
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
·
2 min read
·
Tristan Manalac
